Arylsulphatase A (ASA, EC 3.1.6.1) is a lysosomal enzyme that catalyses cerebroside sulphate degradation. ASA deficiency is associated with metachromatic leucodystrophy (MLD), a rare autosomal recessive disorder, which is characterised by the storage ofcerebroside sulphate. Low ASA activities can be also observed in clinically healthy persons, a condition termed ASA pseudodeficiency. Two mutations responsible for the majority of pseudodeficiency alleles have been defined in the ASA gene. These are both A--G transitions. One causes an asparagine to serine substitution (N350S). The second changes the first polyadenylation signal downstream of the stop codon (1524 + 95A-G), which causes a severe deficiency of one ASA mRNA species. The incidence of the pseudodeficiency allele is estimated to be high in the general population and can be found in families carrying MLD associated mutations. We report a reliable stratagem for detecting the two PD associated mutations separately, which we have applied to a healthy population. Two homozygotes for the N350S and 1524+95A--G mutations were detected, which gives a population frequency of 2-6%. The overall frequencies of the ASA-PD mutations were shown to be 17-5% for the N350S change and 13-0% for the 1524+95A--G change, estimating each mutation separately. In addition, the frequency of both PD associated mutations occurring together on the same chromosome was found to be 12*3% in our population. The study has also allowed us to establish a new control ASA activity range, which was based on assay of blood from persons who had been shown at the DNA level not to carry ASA PD associated mutations.
has also allowed us to establish a new control ASA activity range, which was based on assay of blood from persons who had been shown at the DNA level not to carry ASA PD associated mutations. (JMed Genet 1994; 31:667-671) Arylsulphatase A (ASA, EC 3.1.6.1) is a lysosomal enzyme that catalyses cerebroside sulphate degradation. ASA deficiency is associated with metachromatic leucodystrophy (MLD), a rare autosomal recessive disorder, which is characterised by the storage of cerebroside sulphate.' The accumulation of this substrate can be found in many tissues of MLD patients, but affects mainly the nervous system. MLD can be divided into three major clinical forms: late infantile, juvenile, and adult, and the disease incidence is estimated to be around 1:40 000.2 The ASA gene maps to the long arm of chromosome 22 and spans 3 2 kb of genomic DNA divided into eight exons. 3 The ASA cDNA hybridises to three different mRNA species and would be predicted to code for a protein of 507 amino acids that contains three potential N-glycosylation sites.34 Two mutations in the ASA gene are responsible for about 50% of the MLD associated mutations in the populations studied to date in northern Europe.56 One is a G--A change destroying the splice donor site of intron 2 
(459 + 1 G--A)
and the other is a C-sT transition causing a proline to leucine substitution (P426L) in exon 8. A much more frequent condition, termed ASA pseudodeficiency (PD), is also characterised by low ASA activities. This phenomenon can be seen in clinically healthy persons and its population incidence is estimated to be between 7 3 and 15%. ' 1) were amplified by PCR using the following oligonucleotide primers designed from the ASA genomic sequence (EMBL X52150). (fig 2A, lane 2) . Persons who are heterozygous for the N350S mutation show three fragments after BsrI digestion of fragment A, the 275 bp product from the normal allele, and the 161 bp and 114 bp fragments from the allele carrying the N350S mutation (fig 2A, lanes 3  and 4) . In each case, the mutation was confirmed by direct sequence analysis. 16 were heterozygous for both of them, and five were heterozygous for the N350S mutation alone. One was homozygous for the N350S mutation alone. The 16 persons who were shown to be heterozygous for both mutations were re-screened using the method described by Gieselmann" in order to establish whether both mutations were located on the same chromosome. The results obtained using this method showed that 15 of these 16 persons carried the N350S and 1524+95A-*G mutations on the same chromosome. However, one showed no amplification of the mutant or normal fragments, despite amplification of the internal control fragment, suggesting that the two mutations were located on different chromosomes. (20 of 154 alleles) for the 1524+95A-+G change. These frequencies have been estimated for each mutation separately. In addition, the frequency of both PD associated mutations occurring together on the same chromosome was estimated to be 12-3% (19 of 154 alleles) in our population. The frequency of the PD allele obtained here is higher than the data obtained in the Australian (9 6%)9 and German (73 %)5 populations. This variation may be because of different assays used in each study. The method used here enables the establishment of the frequency of the ASA PD associated mutations alone as well as the frequency of the ASA PD allele carrying both mutations. The study has also allowed us to establish a new control ASA activity range, which was calculated using measurements on persons who had been shown at the DNA level not to carry ASA PD associated mutations. The data obtained in this study will be useful in precise diagnosis of mutation status in families segregating PD associated as well as MLD associated mutations. 
